Radiosensitization of C3H Mouse Mammary Tumours by a 2-Nitroimidazole Drug

Local tumour control has been determined at 150 days after single doses of 240 kV x-rays given with or without 1 mg/g body weight of the hypoxic cell radiosensitizer Ro-07-0582. The dose required to control 50% of the tumours (TCD50) was reduced from 4380 to 2410 rad, yielding an enhancement ratio o...

Descripción completa

Detalles Bibliográficos
Autores principales: Sheldon, P. W., Foster, J. L., Fowler, J. F.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1974
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2009326/
https://www.ncbi.nlm.nih.gov/pubmed/4451633
_version_ 1782136092804251648
author Sheldon, P. W.
Foster, J. L.
Fowler, J. F.
author_facet Sheldon, P. W.
Foster, J. L.
Fowler, J. F.
author_sort Sheldon, P. W.
collection PubMed
description Local tumour control has been determined at 150 days after single doses of 240 kV x-rays given with or without 1 mg/g body weight of the hypoxic cell radiosensitizer Ro-07-0582. The dose required to control 50% of the tumours (TCD50) was reduced from 4380 to 2410 rad, yielding an enhancement ratio of 1·82 ± 0·07 s.e.mean. This compares favourably with the corresponding single dose gain factor for fast neutrons, which was about 1·7.
format Text
id pubmed-2009326
institution National Center for Biotechnology Information
language English
publishDate 1974
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20093262009-09-10 Radiosensitization of C3H Mouse Mammary Tumours by a 2-Nitroimidazole Drug Sheldon, P. W. Foster, J. L. Fowler, J. F. Br J Cancer Articles Local tumour control has been determined at 150 days after single doses of 240 kV x-rays given with or without 1 mg/g body weight of the hypoxic cell radiosensitizer Ro-07-0582. The dose required to control 50% of the tumours (TCD50) was reduced from 4380 to 2410 rad, yielding an enhancement ratio of 1·82 ± 0·07 s.e.mean. This compares favourably with the corresponding single dose gain factor for fast neutrons, which was about 1·7. Nature Publishing Group 1974-12 /pmc/articles/PMC2009326/ /pubmed/4451633 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Articles
Sheldon, P. W.
Foster, J. L.
Fowler, J. F.
Radiosensitization of C3H Mouse Mammary Tumours by a 2-Nitroimidazole Drug
title Radiosensitization of C3H Mouse Mammary Tumours by a 2-Nitroimidazole Drug
title_full Radiosensitization of C3H Mouse Mammary Tumours by a 2-Nitroimidazole Drug
title_fullStr Radiosensitization of C3H Mouse Mammary Tumours by a 2-Nitroimidazole Drug
title_full_unstemmed Radiosensitization of C3H Mouse Mammary Tumours by a 2-Nitroimidazole Drug
title_short Radiosensitization of C3H Mouse Mammary Tumours by a 2-Nitroimidazole Drug
title_sort radiosensitization of c3h mouse mammary tumours by a 2-nitroimidazole drug
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2009326/
https://www.ncbi.nlm.nih.gov/pubmed/4451633
work_keys_str_mv AT sheldonpw radiosensitizationofc3hmousemammarytumoursbya2nitroimidazoledrug
AT fosterjl radiosensitizationofc3hmousemammarytumoursbya2nitroimidazoledrug
AT fowlerjf radiosensitizationofc3hmousemammarytumoursbya2nitroimidazoledrug

Ejemplares similares